In addition to the collection of videos for healthcare professionals provided below, we encourage you to visit our YouTube channel for further informative videos about this rare disease.
This video provides an overview of Hunter syndrome, or mucopolysaccharidosis II (MPS II). In Hunter syndrome, the body has an inability to break down and recycle specific mucopolysaccharides, also known as glycosaminoglycans or GAGs.
This short video describes the early symptoms of Hunter syndrome (MPS II). Symptoms are generally not apparent at birth, but usually start to become noticeable after the first year of life.
In this video, Professor Anna Tylki-Szymanska discusses the early neurological signs and symptoms associated with the accumulation of glycosaminoglycans (GAGs) in Hunter syndrome (MPS II), including cognitive impairment, attention deficit, sleep disturbances, and behavioral difficulties.
Professor Barbara Burton explores why this condition can be difficult to recognize and discusses the importance of identifying MPS II as early as possible.
The “Diagnosis Doesn't Have to be Rare” campaign aims to highlight the challenging diagnostic journey patients with rare diseases often experience and calls for improvement in the diagnostic pathway.
Dr David E. Karas, MD, a pediatric otolaryngologist at the Yale-New Haven Hospital, discusses the key role ENTs play in the diagnosis of syndromes like MPS II.
Surgeons may play an important role in the early diagnosis of Hunter syndrome (MPS II) and other rare metabolic diseases. Dr Christina Lampe from the Department of Pediatric and Adolescent Medicine of the Johannes Gutenberg-University discusses signs that should raise suspicion of these diseases.
The progressive multisystem nature of MPS II requires communication and coordination from many different specialties across the spectrum of healthcare.
Dr Christina Lampe discusses both the preoperative and postoperative anesthesiological risk factors associated with this complex disease.
Professor Joseph Muenzer explains the key findings linked to cardiac valve disease from the Hunter Outcome Survey (HOS).
In this video, Dr Amartino discusses the most common neurological manifestations of Hunter syndrome (MPS II), including seizures, hydrocephalus, carpal tunnel syndrome, and spinal cord compression.
As a child with MPS II goes through adolescence, the gap between pediatric and adult care must be bridged. Here Dr Christina Lampe highlights the importance of embedding transition care as a key part of adolescent health provision.
We encourage you to also visit our YouTube channel for additional videos. Speakers are paid consultants for Takeda.
Hunter syndrome is a
progressive genetic disease
If you suspect Hunter syndrome, refer your patient to a metabolic geneticist for an accurate diagnosis.